Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Tempest Therapeutics Inc
TPSTCurrent price
0.97 USD
+0.03 USD (+3.25%)
Last closed
1.08 USD
Company
www.tempesttx.com
ISIN
US87978U1088
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
27 476 502 USD
Yield for 12 month
-69.60 %
1Y
3Y
5Y
10Y
15Y
TPST
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
18.6 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-381 000 USD
Last Year
-1 814 000 USD
Current Quarter
-155 000 USD
Last Quarter
-88 000 USD
Key Figures TPST
1 year
3 years
5 years
10 years
EBITDA
-31 246 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-54.28 %
PEG Ratio
–
Return On Equity TTM
-289.26 %
Wall Street Target Price
18.6 USD
Revenue TTM
–
Book Value
0.69 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.6 USD
Diluted Eps TTM
-1.6 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TPST
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TPST
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:15
Payout Ratio
–
Last Split Date
28.06.2021
Dividend Date
10.12.2018
Stock Valuation TPST
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
0.3057
Price Book MRQ
1.6221
Financials TPST
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TPST
For 52 weeks
0.86 USD
6 USD
50 Day MA
1.21 USD
Shares Short Prior Month
1 861 925
200 Day MA
2.55 USD
Short Ratio
1.03
Shares Short
3 720 057
Short Percent
17.8 %
BeatStart